Slingshot members are tracking this event:
Having used Halozyme Therapuetics' ENHANZE technology ,Roche’s is awaiting June FDA action date on rituximab in chronic lymphocytic leukemia and non-Hodgkin's lymphoma
Slingshot Insights Explained
Jun 23, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Rituximab, Chronic Lymphocytic Leukemia, Non-hodgkin's Lymphoma, Fda Review, Enhanze